Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment
Diamyd Medical has entered into financing agreements with U.S. investors totaling $125 million and announced full enrollment in its Phase 3 trial.
third-news.com
March 23, 2026 at 7:36 AM
Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion
Diamyd Medical announces successful financing agreements totaling $125 million and the completion of its Phase 3 clinical trial for Type 1 diabetes.
third-news.com
March 23, 2026 at 7:35 AM
Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
Diamyd Medical's Phase 3 DIAGNODE-3 Trial Database Finalized for Interim Analysis#Sweden#Stockholm#Diamyd_Medical#DIAGNODE-3#retogatein
Diamyd Medical's Phase 3 DIAGNODE-3 Trial Database Finalized for Interim Analysis
Diamyd Medical has successfully completed the clinical database for the interim analysis in its Phase 3 trial, DIAGNODE-3, assessing retogatein for type 1 diabetes treatment.
third-news.com
February 24, 2026 at 8:10 AM
Diamyd Medical's Phase 3 DIAGNODE-3 Trial Database Finalized for Interim Analysis#Sweden#Stockholm#Diamyd_Medical#DIAGNODE-3#retogatein
Diamyd Medical Gains Significant Patent Notice for Retogatein in the U.S.#USA#Stockholm#Type_1_Diabetes#Diamyd_Medical#retogatein
Diamyd Medical Gains Significant Patent Notice for Retogatein in the U.S.
Diamyd Medical recently announced a vital patent allowance from the USPTO for retogatein, marking progress in its diabetes treatment efforts.
third-news.com
February 9, 2026 at 8:24 AM
Diamyd Medical Gains Significant Patent Notice for Retogatein in the U.S.#USA#Stockholm#Type_1_Diabetes#Diamyd_Medical#retogatein
Diamyd Medical Secures Key Patent Allowance for Retogatein in the US Market#USA#Stockholm#Type_1_Diabetes#Diamyd_Medical#retogatein
Diamyd Medical Secures Key Patent Allowance for Retogatein in the US Market
Diamyd Medical has received a Notice of Allowance from the USPTO for a patent on retogatein, an important immunotherapy for type 1 diabetes.
third-news.com
February 9, 2026 at 8:23 AM
Diamyd Medical Secures Key Patent Allowance for Retogatein in the US Market#USA#Stockholm#Type_1_Diabetes#Diamyd_Medical#retogatein
